Mepolizumab to Prevent Exacerbations of COPD with an Eosinophilic Phenotype
Treatment with mepolizumab led to a lower annualized rate of moderate or severe exacerbations when added to background triple inhaled therapy among patients with COPD and an eosinophilic phenotype. (Funded by GSK; MATINEE ClinicalTrials.gov number, NCT04133909.).
Authors
- Nicolás Roche (ORCID: https://orcid.org/0000-0002-3162-5033)
- Gerard J. Criner (ORCID: https://orcid.org/0000-0003-1267-3483)
- Mona Bafadhel (ORCID: https://orcid.org/0000-0002-9993-2478)
- Jean Bourbeau (ORCID: https://orcid.org/0000-0002-7649-038X)
- Dalal Mouneimne
- Alberto Papi (ORCID: https://orcid.org/0000-0002-6924-4500)
- Frank C. Sciurba (ORCID: https://orcid.org/0000-0001-7468-2225)
- Stephanie Korn (ORCID: https://orcid.org/0009-0001-2239-5029)
- Jeff Min (ORCID: https://orcid.org/0000-0003-4633-6792)
- Stefanie Kolterer
- Ian Pavord (ORCID: https://orcid.org/0000-0002-4288-5973)
- MeiLan K. Han
- Fernando J. Martinez
- Karen Miller (ORCID: https://orcid.org/0000-0002-2094-2455)
- Bhabita Mayer
- Stephanie A. Christenson
- John Fletcher
Institutions
- University of Massachusetts Chan Medical School (US)
- University of Pittsburgh (US)
- University of California, San Francisco (US)
- King's College London (GB)
- University of Ferrara (IT)
- Université Paris Cité (FR)
- McGill University Health Centre (CA)
- University Hospital Heidelberg (DE)
- National Institute for Health and Care Research (GB)
- University of Oxford (GB)
- Assistance Publique – Hôpitaux de Paris (FR)
- Michigan Medicine (US)
- MRC Biostatistics Unit (GB)
- Institut Cochin (FR)
- Oxford BioMedica (United Kingdom) (GB)
- Temple University (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-04-30
- DOI
- https://doi.org/10.1056/nejmoa2413181
- Citations
- 74
- Primary Topic
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Type
- article
- Field-Weighted Citation Impact
- 112.36
Funders
- GlaxoSmithKline